Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms

JAK Inhibitor in CALR-Mutant Myelofibrosis

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca2+: some mechanistic and therapeutic implications

(2014) V Shivarov et al.   Blood Cancer Journal

The calcineurin-NFAT pathway negatively regulates megakaryopoiesis

(2013) A. Zaslavsky et al.   BLOOD

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

New mutations and pathogenesis of myeloproliferative neoplasms

(2011) W. Vainchenker et al.   BLOOD

Calreticulin: non-endoplasmic reticulum functions in physiology and disease

(2009) Leslie I. Gold et al.   FASEB JOURNAL

Getting In and Out from Calnexin/Calreticulin Cycles

(2008) Julio J. Caramelo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY